by
Sheena Carter;
Amy Hutchinson;
Salathiel Kendrick-Allwood;
Nathalie Maitre;
Ira Adams-Chapman;
Kristi L Watterberg;
Tracy L Nolen;
Shawn Hirsch;
Carol A Cole;
Michael C Cotten;
William Oh;
Brenda Poindexter;
KM Zaterka-Baxter;
A Das;
CB Lacy;
AM Scorsone;
AF Duncan;
SB DeMauro;
RF Goldstein;
TT Colaizy;
DE Wilson-Costello;
IB Purdy;
SR Hintz;
RJ Heyne;
GJ Myers;
J Fuller;
S Merhar;
HM Harmon;
M Peralta-Carcelen;
HW Kilbride;
BR Vohr;
G Natarajan;
H Mintz-Hittner;
GE Quinn;
DK Wallace;
RJ Olson;
FH Orge;
I Tsui;
M Gaynon;
Y-G He;
TW Winter;
MB Yang;
KM Haider;
MS Cogen;
D Hug;
DL Bremer;
JP Donahue;
WR Lucas;
DL Phelps;
RD Higgins
Objective: This study evaluates the 24-month follow-up for the NICHD Neonatal Research Network (NRN) Inositol for Retinopathy Trial. Study design: Bayley Scales of Infants Development-III and a standardized neurosensory examination were performed in infants enrolled in the main trial. Moderate/severe NDI was defined as BSID-III Cognitive or Motor composite score <85, moderate or severe cerebral palsy, blindness, or hearing loss that prevents communication despite amplification were assessed. Results: Primary outcome was determined for 605/638 (95%). The mean gestational age was 25.8 ± 1.3 weeks and mean birthweight was 805 ± 192 g. Treatment group did not affect the risk for the composite outcome of death or survival with moderate/severe NDI (60% vs 56%, p = 0.40). Conclusions: Treatment group did not affect the risk of death or survival with moderate/severe NDI. Despite early termination, this study represents the largest RCT of extremely preterm infants treated with myo-inositol with neurodevelopmental outcome data.
by
Carmen M Dickinson-Copeland;
Lilly Cheng Immergluck;
Maria Britez;
Fengxia Yan;
Ruijin Geng;
Mike Edelson;
Salathiel Kendrick-Allwood;
Katarzyna Kordas
Lead (Pb) is a naturally occurring, highly toxic metal that has adverse effects on children across a range of exposure levels. Limited screening programs leave many children at risk for chronic low-level lead exposure and there is little understanding of what factors may be used to identify children at risk. We characterize the distribution of blood lead levels (BLLs) in children aged 0–72 months and their associations with sociodemographic and area-level variables. Data from the Georgia Department of Public Health’s Healthy Homes for Lead Prevention Program surveillance database was used to describe the distribution of BLLs in children living in the metro Atlanta area from 2010 to 2018. Residential addresses were geocoded, and “Hotspot” analyses were performed to determine if BLLs were spatially clustered. Multilevel regression models were used to identify factors associated with clinical BBLs (≥5 µg/dL) and sub-clinical BLLs (2 to <5 µg/dL). From 2010 to 2018, geographically defined hotspots for both clinical and sub-clinical BLLs diffused from the city-central area of Atlanta into suburban areas. Multilevel regression analysis revealed non-Medicaid insurance, the proportion of renters in a given geographical area, and proportion of individuals with a GED/high school diploma as predictors that distinguish children with BLLs 2 to <5 µg/dL from those with lower (<2 µg/dL) or higher (≥5 µg/dL) BLLs. Over half of the study children had BLLs between 2 and 5 µg/dL, a range that does not currently trigger public health measures but that could result in adverse developmental outcomes if ignored.